摘要
目的探讨雷贝拉唑联合莫沙必利治疗反流性食管炎的临床疗效。方法选取医院2016年4月至2017年4月收治的反流性食管炎患者68例,随机均分为对照组和观察组。对照组患者口服雷贝拉唑,观察组患者在对照组治疗基础上口服莫沙必利,均治疗8周。结果观察组患者的临床症状改善总有效率为85.29%,显著高于对照组的52.94%(χ~2=8.336,P=0.004<0.05);观察组患者的胃镜下食管炎症改善总有效率为82.35%,显著高于对照组的50.00%(χ~2=7.950,P<0.05);两组患者治疗期间的不良反应比较无明显差异(χ~2=0.731,P=0.393>0.05)。结论雷贝拉唑联合莫沙必利治疗反流性食管炎,临床疗效显著,值得临床推广。
Objective To investigate the clinical effect rabeprazole combined with mosapride in the treatment of reflux esophagitis.Methods Totally 68 patients with reflux esophagitis admitted to our hospital from April 2016 to April 2017 were selected and randomly divided into the control group and the observation group,34 cases in each group. The control group was treated with rabeprazole,on this basis,the observation group was treated with mosapride. The two groups were treated for 8 weeks. Results The total effective rate of improvement of clinical symptoms in the observation group was 85. 29%, which was significantly higher than 52. 94% in the control group（ χ2= 8. 336; P = 0. 004 0. 05）. The total effective rate of improvement of endoscopic esophagitis in the observation group was 82. 35%,which was significantly higher than 50. 00% in the control group（ χ2= 7. 950, P〈0. 05）. There were significant differences in the incidence rates of adverse reactions between the two groups during treatment（ χ2= 0. 731, P = 0. 393 0. 05）. Conclusion Rabeprazole combined with mosapride is effective in the treatment of reflux esophagitis,which is worthy of clinical promotion.
作者
黄艳飞
韦凤银
韦雅毅
Huang Yanfei;Wei Fengyin;Wei Yayi(Dahua Yao Autonomous County People＇s Hospital, Hechi, Guangxi, China 53080)
出处
《中国药业》
CAS
2018年第11期72-74,共3页
China Pharmaceuticals
关键词
反流性食管炎
莫沙必利
雷贝拉唑
疗效
reflux esophagitis
mosapride
rabeprazole
curative effect
